From TheStreet:
Pharmaceutical companies face increased risks if they do not have enough new drugs in the pipeline to replace those with expiring patents, or if tests on new drugs under development are negative, or new drugs are not approved by the Food and Drug Administration.
So, what are the worst pharmaceutical companies investors should be selling? Here are the top three: